

**Amendments to the Specification**

Please replace the paragraph at page 7, lines 3 through 18 with the following amended paragraph:

In a preferred embodiment, the thrombin peptide derivative comprises a serine esterase conserved sequence and a polypeptide having a more specific thrombin amino acid sequence Arg-Gly-Asp-Ala (SEQ ID NO 3). The Asp-Ala of the thrombin receptor binding domain comprise the first two amino acids of the serine esterase conserved sequence. One example of a thrombin peptide derivative of this type comprises Arg-Gly-Asp-Ala-Cys-X<sub>1</sub>-Gly-Asp-Ser-Gly-Gly-Pro-X<sub>2</sub>-Val (SEQ ID NO 4). X<sub>1</sub> and X<sub>2</sub> are as defined above. When the thrombin peptide derivative comprises SEQ ID NO 4, it preferably has the amino acid sequence of SEQ ID NO 5 (Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val) (~~Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val~~) or an *N*-terminal truncated fragment thereof, provided that zero, one, two or three amino acids at positions 1-9 in the thrombin peptide derivative differ from the amino acid at the corresponding position of SEQ ID NO 5. Preferably, the amino acids in the thrombin peptide derivative which differ from the corresponding amino acid in SEQ ID NO 5 are conservative substitutions, and are more preferably highly conservative substitutions ~~substitutions~~. An “*N*-terminal truncated fragment” refers to a fragment remaining after removing an amino acid or block of amino acids from the *N*-terminus, preferably a block of no more than six amino acids, more preferably a block of no more than three amino acids.